Short report: Multicenter phase II trial of brequinar sodium in patients with advanced melanoma

Abstract

Summary: Seventeen patients with advanced melanoma and responses. The toxicity was moderate. We conclude that, at no prior exposure to chemotherapy were treated with bre- this dose and schedule, brequinar has no activity in advanced quinar sodium as first-line chemotherapy. Brequinar was given at median weekly dose of 1200 mg/m2 intravenously. In 14 patients evaluable for efficacy, there were no objective responses. The toxicity was moderate. We conclude that at this dose and schedule brequinar has no activity in advanced metanoma. © 1992 Kluwer Academic Publishers.